Zhang Y, Song L, Zeng L, Xiong Y, et al. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study. BMC Cancer 2022;22:952.
PMID: 36064386